Snijders Antoine M, Fridlyand Jane, Mans Dorus A, Segraves Richard, Jain Ajay N, Pinkel Daniel, Albertson Donna G
Cancer Research Institute, University of California San Francisco, San Francisco, CA 94143-0808, USA.
Oncogene. 2003 Jul 10;22(28):4370-9. doi: 10.1038/sj.onc.1206482.
Tumors with defects in mismatch repair (MMR) show fewer chromosomal changes by cytogenetic analyses than most solid tumors, suggesting that a greater proportion of the alterations required for malignancy occur in genes with nucleotide sequences susceptible to errors normally corrected by MMR. Here, we used genome-wide microarray comparative genomic hybridization to carry out a higher resolution evaluation of the effect of MMR competence on genomic alterations occurring in 20 cell lines and to determine if characteristic aberrations arise in MMR-proficient and -deficient HCT116 cells undergoing selection for methotrexate resistance. We observed different spectra of aberrations in MMR-proficient compared to -deficient cell lines, as well as among cell lines with different types of MMR-deficiency. We also observed different genetic routes to drug resistance. Resistant MMR-deficient cells most frequently displayed no copy number alterations (16/29 cell pools), whereas all MMR-proficient cells had unique abnormalities involving chromosome 5, including amplicons centered on the target gene, DHFR and/or a neighboring novel locus (7/13 pools). These observations support the concept that tumor genomes are shaped by selection for alterations that promote survival and growth advantage, as well as by the particular dysfunctions in genes responsible for maintenance of genetic integrity.
与大多数实体瘤相比,错配修复(MMR)存在缺陷的肿瘤经细胞遗传学分析显示出的染色体变化较少,这表明恶性肿瘤所需的更大比例的改变发生在核苷酸序列易出错的基因中,而这些错误通常由MMR纠正。在此,我们使用全基因组微阵列比较基因组杂交技术,对MMR功能对20种细胞系中发生的基因组改变的影响进行了更高分辨率的评估,并确定在经历甲氨蝶呤耐药性选择的MMR功能正常和缺陷的HCT116细胞中是否会出现特征性畸变。我们观察到,与MMR缺陷的细胞系相比,MMR功能正常的细胞系中的畸变谱不同,并且在具有不同类型MMR缺陷的细胞系之间也存在差异。我们还观察到了不同的耐药遗传途径。耐药的MMR缺陷细胞最常表现为无拷贝数改变(29个细胞池中的16个),而所有MMR功能正常的细胞都有涉及5号染色体的独特异常,包括以靶基因二氢叶酸还原酶(DHFR)和/或相邻新位点为中心的扩增子(13个细胞池中的7个)。这些观察结果支持了这样一种概念,即肿瘤基因组是由对促进生存和生长优势的改变的选择以及负责维持遗传完整性的基因中的特定功能障碍所塑造的。